Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

Toxicity and efficacy of chronomodulated chemotherapy: a systematic review

(2022) Markella I Printezi et al.   LANCET ONCOLOGY

The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas

(2021) Benoit You et al.   CANCER TREATMENT REVIEWS

Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.

(2021) Benoit You et al.   JOURNAL OF CLINICAL ONCOLOGY

The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review

(2021) Ambroise Lauby et al.   Cancers

CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial

(2020) Benoît You et al.   CLINICAL CANCER RESEARCH

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

(2020) William P. Tew et al.   JOURNAL OF CLINICAL ONCOLOGY

847P The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands

(2020) L. Van Wagensveld et al.   ANNALS OF ONCOLOGY

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

(2019) Olivier Colomban et al.   CLINICAL CANCER RESEARCH

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

(2019) Krishnansu S. Tewari et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

(2019) Andrew R Clamp et al.   LANCET

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

(2018) Glenn Heller et al.   JOURNAL OF CLINICAL ONCOLOGY

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

(2018) Willemien J. van Driel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

(2016) Alexi A. Wright et al.   JOURNAL OF CLINICAL ONCOLOGY

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

(2013) F. Collinson et al.   CLINICAL CANCER RESEARCH

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study)

(2013) Benoit You et al.   GYNECOLOGIC ONCOLOGY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE